EDIT · Project

Early Bladder Cancer Detection and Treatment Using Gold Nanoparticles and Advanced Imaging

healthPrototypeTRL 4Thin data (2/5)

edit-h2020.eu

Bladder cancer is one of the most expensive cancers to manage because patients need constant check-ups and repeated treatments, often for years. The EDIT team developed tiny gold particles that, when placed inside the bladder, light up under special imaging — almost like painting suspicious tissue with a highlighter so doctors can spot cancer at its earliest stages. The same gold particles can then be heated with light to destroy just the cancerous cells without surgery. Think of it as a smart search-and-destroy system that finds trouble before it becomes serious and eliminates it on the spot.

By the numbers

EUR 4,317,160

EU funding for development

consortium partners

countries in consortium

SME partners involved

50%

industry ratio in consortium

project deliverables completed

The business problem

What needed solving

Bladder cancer has the highest cost per patient among all cancers due to endless follow-up visits and repeated weekly treatments. Current detection methods miss early-stage tumors, leading to frequent relapse and progression to aggressive forms. Hospitals and healthcare systems need a non-invasive way to catch bladder cancer earlier and treat it in the same procedure, reducing both patient suffering and the massive ongoing treatment costs.

The solution

What was built

The team built a combined ultrasound elastography and photoacoustic imaging platform that uses engineered gold nanorods to detect and treat early bladder cancer. They also developed machine learning algorithms for analyzing the imaging data, completing 10 deliverables over the 4-year project at proof-of-concept level.

Audience

Who needs this

Urological medical device manufacturers looking for next-generation bladder imaging systemsNanomedicine companies developing targeted gold nanoparticle therapiesAI diagnostics firms building cancer detection algorithms for medical imagingHospital groups and urology clinics seeking to reduce bladder cancer follow-up costsPharmaceutical companies interested in theranostics (combined diagnosis and therapy)

Business applications

Who can put this to work

Medical device manufacturing

enterprise

Target: Companies developing urological diagnostic and imaging equipment

If you are a medical device manufacturer developing urological imaging systems — this project built a combined ultrasound elastography and photoacoustic imaging platform for bladder examination. It detects pre-cancerous changes at few-cells resolution using targeted gold nanorods, potentially replacing invasive cystoscopy procedures. The consortium of 10 partners across 5 countries validated the approach in preclinical settings.

Pharmaceutical and nanomedicine

SME

Target: Nanomedicine companies developing targeted cancer therapies

If you are a nanomedicine company working on targeted cancer treatments — this project engineered gold nanorods that serve dual purpose: diagnostic imaging contrast agents and photothermal therapy effectors. The particles target the extracellular matrix, a common biomarker across bladder, breast, colorectal, and prostate cancers. With EUR 4,317,160 in EU funding and 3 SME partners already involved, the platform is ready for further commercial development.

Health IT and AI diagnostics

mid-size

Target: Companies building AI-powered medical imaging analysis software

If you are an AI diagnostics company looking for new clinical applications — this project developed machine learning algorithms for analyzing combined ultrasound and photoacoustic imaging data of bladder tissue. The algorithms detect structural and mechanical changes in tissue that signal early cancer. With 10 deliverables completed over 4 years, the dataset and models could be adapted for other solid tumor detection.

Frequently asked

Quick answers

What would it cost to license or adopt this technology?

The project was funded with EUR 4,317,160 under FET-Open, indicating early-stage research. Licensing terms would need to be negotiated with the coordinator, Ospedale San Raffaele in Italy, and potentially with the 3 SME partners who contributed to development. Based on available project data, no commercial pricing has been established yet.

Can this scale to industrial production?

The gold nanorods and imaging platform were validated at preclinical level as a proof of concept. Scaling to clinical use would require regulatory approval and manufacturing partnerships for the gold nanorod sensors. The consortium includes 5 industry partners (50% of the consortium), which suggests some manufacturing capability exists within the team.

What is the IP situation and licensing availability?

As an EU-funded RIA project with 10 partners across 5 countries, IP is likely shared among consortium members. The 3 SME partners may hold specific IP on components like gold nanorod manufacturing or imaging software. Contact the coordinator at Ospedale San Raffaele for licensing discussions.

What regulatory approvals are needed?

This is a medical device and nanomedicine combination product, requiring extensive regulatory clearance. The project completed preclinical validation but clinical trials would still be needed. The gold nanorods used intravesically would need to meet biocompatibility and safety standards under EU MDR and potentially EMA review for the nanomedicine component.

How long before this reaches the market?

The project ran from 2018 to 2022 and achieved proof-of-concept level results. Based on available project data, clinical trials have not yet been completed. A realistic timeline to market would require several additional years of clinical validation and regulatory approval.

Can this technology be applied beyond bladder cancer?

Yes — the project objective explicitly states that structural and mechanical modification of the extracellular matrix is a common denominator for invasive breast, colorectal, prostate, and bladder cancers. The platform was designed to pave the way for earlier management of other solid tumors and bladder-related pathologies.

What technical support is available for adoption?

The consortium includes 4 universities and 1 research organization providing deep scientific expertise, plus 5 industry partners for technical implementation. Machine learning algorithms were developed and documented as a formal deliverable. The project website at edit-h2020.eu may provide additional technical resources.

Consortium

Who built it

The EDIT consortium is well-balanced for an emerging medical technology, with 10 partners across 5 countries (Greece, Israel, Italy, Netherlands, UK). The 50% industry ratio — 5 industry partners including 3 SMEs — signals genuine commercial interest beyond pure academic research. The coordinator, Ospedale San Raffaele in Milan, is one of Europe's leading research hospitals, lending strong clinical credibility. With 4 universities providing fundamental research and 1 dedicated research organization, the science backbone is solid. The multi-country spread across major medtech markets (Italy, Netherlands, UK) and strong R&D nations (Israel, Greece) gives the technology exposure to diverse regulatory environments and market entry points. For a business partner, the presence of 3 SMEs suggests there are already smaller companies positioned to commercialize specific components of the platform.

OSPEDALE SAN RAFFAELE SRLCoordinator · IT
LIME TECHNOLOGY IKEparticipant · EL
WEIZMANN INSTITUTE OF SCIENCEparticipant · IL
OSM-DAN LTDparticipant · IL
CONSIGLIO NAZIONALE DELLE RICERCHEparticipant · IT
UNIVERSITA DEGLI STUDI DI MILANOparticipant · IT
ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNAparticipant · IT
FUJIFILM SONOSITE BVparticipant · NL
UNIVERSITA VITA-SALUTE SAN RAFFAELEthirdparty · IT

How to reach the team

Ospedale San Raffaele SRL, Milan, Italy — contact via hospital's technology transfer office

Order a report on this consortium See OSPEDALE SAN RAFFAELE SRL profile →

Next steps

Talk to the team behind this work.

Want an introduction to the EDIT team to discuss licensing the imaging platform or gold nanorod technology? SciTransfer can arrange a direct meeting with the right people in the consortium.

Order a report on this topic More in Health & Biomedical